Skip to main content
SpringerLink
Log in

High-Grade Poorly Differentiated Neuroendocrine Carcinomas of the Gastroenteropancreatic System: from Morphology to Proliferation and back

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Poorly differentiated neuroendocrine carcinomas (PDNECs) of the gastroenteropancreatic system (GEP) are a heterogeneous group of aggressive malignancies with a high propensity for distant metastases and an ominous prognosis. They have traditionally been divided into small and large cell subtypes on morphological grounds. However, histological diagnosis needs to be supported by immunohistochemistry to avoid possible misdiagnoses either with the more frequent poorly differentiated adenocarcinomas and squamous cell carcinomas or with lymphomas and mesenchymal neoplasms. Although it is well known that GEP PDNECs are associated with a poor prognosis, data from some published studies seem to suggest that there is a fraction of patients with PDNECs who have better survival than expected. GEP PDNECs are currently classified according to the criteria proposed in the 2010 WHO classification. They are simply called neuroendocrine carcinomas (NECs) and are defined by mitotic count >20 × 10 HPF and/or Ki-67 labeling index >20 %. However, a few recent papers have indicated that some NECs, as defined by the 2010 WHO scheme, do not show a poorly differentiated morphology as expected. This category seems to show a better prognosis and, especially, does not respond to cisplatin-based chemotherapy, which represents the goal standard therapeutic approach to high-grade PDNECs. In the present review, the main morphological, immunohistochemical, and prognostic features will be discussed as well as the opportunity to introduce a new category characterized by well to moderately differentiated morphology associated with high proliferation (mitotic count >20 × 10 HPF and/or Ki-67 index >20 %).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Furlan D, Bernasconi B, Uccella S, Cerutti R, Carnevali I, Capella C (2005) Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites. Clin Cancer Res 11:1765-1775

    Article  CAS  PubMed  Google Scholar 

  2. Yachida S, Vakiani E, White CM, et al (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36:173-184

    Article  PubMed Central  PubMed  Google Scholar 

  3. Yao JC, Shah MH, Ito T, et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523

    Article  CAS  PubMed  Google Scholar 

  4. Fazio N, Scarpa A, Falconi M (2014) Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice. Curr Med Chem 21:1017-1025

    Google Scholar 

  5. Moertel C, Kvols L, O’Connel M, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227-232

    Article  CAS  PubMed  Google Scholar 

  6. Smith J, Reidy-Lagunes D (2013) The management of extrapulmonary poorly differentiated (high grade) neuroendocrine carcinomas. Semin Oncol 40:100-108

    Article  PubMed  Google Scholar 

  7. La Rosa S, Marando A, Sessa F, Capella C (2012) Mixed adenoneuroendocrine carcinomas (MANECs) of the gastrointestinal tract: an update. Cancers 4:11-30

    Article  PubMed Central  PubMed  Google Scholar 

  8. Solcia E, Klöppel G, Sobin LH, et al (2000) Histological typing of endocrine tumours. WHO International Histological Classification of Tumours, 2nd Edition. Springer, Berlin

    Book  Google Scholar 

  9. Rindi G, Arnold R, Bosman FT, et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO classification of tumours of the digestive system. IARC Press, Lyon, pp 13-14

    Google Scholar 

  10. Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I (2006) Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol 30:945-953

    Article  PubMed  Google Scholar 

  11. Shia J, Tang LH, Weiser MR, et al (2008) Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 32:719-731

    Article  PubMed  Google Scholar 

  12. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C (2012) Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol 36:601-611

    Article  PubMed  Google Scholar 

  13. Basturk O, Hruban RH, Adsay NV, et al (2014) Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 38:437-447

    Article  PubMed  Google Scholar 

  14. Volante M, Birocco N, Gatti G, Duregon E, Lorizzo K, Fazio N, Scagliotti GV, Papotti M (2014) Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Hum Pathol 45:665-673

    Google Scholar 

  15. Rindi G, Bordi C, La Rosa S, Solcia E, Delle Fave G (2011) Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig Liver Dis 43(Suppl 4):S356-S360

    Article  PubMed  Google Scholar 

  16. Corrin B, Gilby ED, Jones NF, Patrick J (1973) Oat cell carcinoma of the pancreas with ectopic ACTH secretion. Cancer 31:1523-1527

    Article  CAS  PubMed  Google Scholar 

  17. Wick MR (2000) Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 17:194-203

    CAS  PubMed  Google Scholar 

  18. DeLellis RA, Shin SJ, Treaba DO (2010) Immunohistology of endocrine tumors. In: Dabbs DJ (ed). Diagnostic Immunohistochemistry: Theranostic and genomic applications. Saunders Elsevier, Philadelphia, pp 291-339

    Google Scholar 

  19. Barbareschi M, Roldo C, Zamboni G, Capelli P, Cavazza A, Macri E, Cangi MG, Chilosi M, Doglioni C (2004) CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol 28:1169-1176

    Article  PubMed  Google Scholar 

  20. La Rosa S, Rigoli E, Uccella S, Chiaravalli AM, Capella C (2004) CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch 445:248-254

    Article  CAS  PubMed  Google Scholar 

  21. La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, Capella C (2010) TTF1 expression in normal lung neuroendocrine cells and related tumors: Immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 457:497-507

    Article  PubMed  Google Scholar 

  22. Hermann G, Konukiewitz B, Schmitt A, Perren A, Klöppel G (2011) Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch 459:147-154

    Article  CAS  PubMed  Google Scholar 

  23. Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A (2008) Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 32:420-425

    Article  PubMed  Google Scholar 

  24. Koo J, Zhou X, Moschiano E, De Peralta-Venturina M, Mertens RB, Dhall D (2013) The immunohistochemical expression of Islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol 24:184-190

    Article  CAS  PubMed  Google Scholar 

  25. Agaimy A, Erlenbach-Wünsch K, Konukiewitz B, Schmitt AM, Rieker RJ, Vieth M, Kiesewetter F, Hartmann A, Zamboni G, Perren A, Klöppel G (2013) ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol 26:995-1003

    Article  CAS  PubMed  Google Scholar 

  26. La Rosa S, Marando A, Gatti G, Rapa I, Volante M, Papotti M, Sessa F, Capella C (2013) Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases. Hum Pathol 44:1391-1399

    Article  PubMed  Google Scholar 

  27. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E (1996) Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch 429:323-333

    Article  PubMed  Google Scholar 

  28. Power DG, Asmis TR, Tang LH, Brown K, Kemeny NE (2011). High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. Med Oncol Suppl1:S169-S174

    Article  Google Scholar 

  29. Akintola-Ogunremi O, Pfeifer JD, Tan BR, et al (2003) Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomas. Am J Surg Pathol 27:1551-1558

    Article  PubMed  Google Scholar 

  30. Ishikubo T, Akagi K, Kurosumi M, Yamaguchi K, Fujimoto T, Sakamoto H, Tanaka Y, Ochiai A (2006) Immunohistochemical and mutational analysis of c-kit in gastrointestinal neuroendocrine cell carcinoma. Jpn J Clin Oncol 36:494-498

    Article  PubMed  Google Scholar 

  31. Gross DJ, Munter G, Bitan M, et al (2006) The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 13:535-540

    Article  CAS  PubMed  Google Scholar 

  32. Pages F, Galon J, Dieu-Nosjean MC Tartour E, Sautès-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093-1102

    Article  CAS  PubMed  Google Scholar 

  33. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virschows Arch 2006; 449:395-401

    Article  CAS  Google Scholar 

  34. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) Pathology and genetics of tumours of endocrine organs. World Health Organization Classification of Tumours. IARC Press, Lyon

    Google Scholar 

  35. La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E (2011) Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 42:1373-1384

    Article  PubMed  Google Scholar 

  36. Volante M, Daniele L, Asioli S et al (2013) Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases. Am J Surg Pathol 37:606-612

    Article  PubMed  Google Scholar 

  37. Basturk O, Yang Z, Tang LH, et al (2013) Increased (>20 %) Ki67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (PanNETs) correlates with decreased overall survival. Mod Pathol 26(Suppl 2):423A

    Google Scholar 

  38. Vélayoudom-Céphise FL, Duvillard P, Foucan L, et al (2013) Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 20:649-657

    Article  PubMed  Google Scholar 

  39. Travis WD (2010) Advances in neuroendocrine lung tumors. Ann Oncol Suppl 7:vii65-71

    Google Scholar 

  40. Sorbye H, Welin S, Langer SW, et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24:152-160

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors dedicate this paper to Prof. Capella who has been our teacher for such a long time.

Author information

Authors and Affiliations

  1. Department of Pathology, Ospedale di Circolo, Viale Borri 57, 21100, Varese, VA, Italy

    Stefano La Rosa

  2. Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy

    Fausto Sessa

Authors
  1. Stefano La Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fausto Sessa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano La Rosa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

La Rosa, S., Sessa, F. High-Grade Poorly Differentiated Neuroendocrine Carcinomas of the Gastroenteropancreatic System: from Morphology to Proliferation and back. Endocr Pathol 25, 193–198 (2014). https://doi.org/10.1007/s12022-014-9316-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-014-9316-9

Keywords

Search

Navigation